My question is to other here, in past experience is this normal in the small biotech investing scenario? I know set backs and extended timelines are to be expected but the radio silence is odd.
PRO 140 has very weak CCR5 affinity..that is why there a low side effects. The trade off is usually potency = efficacy, and sub therapeutic potency means low AE's. This is an unmet disease state..Efficacy trumps AE's. Who cares if your AE profile is manageable when efficacy is compromised. This is HIV...NOT ACNE!
GES, I agree with most of what you said except about the management has invested. ONLY one member of management has any meaningful amount of cash in the deal and that is Tony C who gave that rousing introduction to us a year ago February. He has been pretty silent since then but at least he has $200K coming in a year! The thing that steams my chili is that every day Nader wakes up and ties his shoes to go to the office or chase another nonexistent institution he is earning at least $2,000 a day. If I was in that position I would be saying things are beautiful also!!
News 
Market Data 
Discover 
AI
